Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML), or a related condition called AML with myelodysplastic syndrome features, based on recognised medical classification systems
- People aged 14 to 60 years old (male or female)
- People whose general physical health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (a score of 0–2 on the ECOG scale)
- People whose recent blood and heart test results (taken within 7 days before starting treatment) fall within acceptable ranges, including: liver function markers (bilirubin, AST, ALT), kidney function (creatinine), heart muscle enzymes, and a heart pumping strength (ejection fraction) of more than 50% on an ultrasound of the heart
- People who are able to provide signed consent before any study procedures begin — or, where the patient's condition makes this difficult, consent may be signed by a legal guardian or close family member
Who may not be able to join:
- People whose AML is a specific subtype known as Acute Promyelocytic Leukaemia with a PML-RARA genetic change
- People whose AML involves a specific genetic change called BCR-ABL
- People who have already received treatment for their AML (though limited prior use of hydroxyurea or low-dose cytarabine to reduce cancer cell levels may be acceptable — confirm with trial site)
- People who currently have another active cancer in another part of the body that requires treatment
- People with certain active heart conditions, including: poorly controlled or symptomatic chest pain (angina); a heart attack within the 6 months before joining; a heart rhythm problem that requires medication or causes significant symptoms; or poorly controlled or symptomatic heart failure above a mild level
- People with serious ongoing infections, specifically unresolved tuberculosis or a fungal lung infection called pulmonary aspergillosis
- People whom the trial researchers consider unsuitable for participation for other medical reasons (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Phone: 13132507161
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-free survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.